Happy Monday all, it’s Day4 of #ESMO25
My hot picks for today:

✅Updated data on #SWOG1801 & #NADINA

✅#SafeStopTrial (early discontinuation of CPI in CR/PR)

✅#STAMP (adj pembro in Merkel Cell)

✅Phase1 #IMA203 for 👁️Uveal Melanoma in Presidential session

@oncoalert.bsky.social @myesmo.bsky.social

Thanks to #NADINA clinical trial, led by MIA with Netherlands colleagues, #neoadjuvant (pre-surgery) use of combination #immunotherapy drugs nivolumab and ipilimumab approved by #PBAC & will be listed on #PBS as treatment for Stage III melanoma. @9news.bsky.social
@gvlongphdmd.bsky.social

Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma | NEJM In phase 1–2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy. In this phase 3 trial, we randomly assig...

So that’s it for 2024!

Oncology Highlights:
⭐️ 1) #NADINA was a brave and intelligently designed trial which deftly answered an important clinical question in #Melanoma

🥈2) my runner up #ADRIATIC. Hope in and area of need and further evidence of the scope and potential of #IO

#LCSM #Oncsky #Medsky